Decreased NT-3 plasma levels and platelet serotonin content in patients with hypochondriasis

Journal of Psychosomatic Research

Volumn 65, Issue 5, 2008, Pages 435-439

  Brondino, Natascia ^a   Lanati, Niccolò ^a   Barale, Francesco ^a   Martinelli, Valentina ^a   Politi, Pierluigi ^a   Geroldi, Diego ^a   Emanuele, Enzo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Hypochondriasis; Neurotrophins; Platelet; Serotonin

Indexed keywords

NEUROTROPHIN 3; SEROTONIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTENT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPOCHONDRIASIS; MALE; MULTIVARIATE ANALYSIS; PROTEIN BLOOD LEVEL; SEROTONIN BLOOD LEVEL; SEROTONINERGIC SYSTEM; THROMBOCYTE;

ADULT; AGED; BLOOD PLATELETS; BRAIN; FEMALE; HUMANS; HYPOCHONDRIASIS; MALE; MIDDLE AGED; NEUROTROPHIN 3; PERSONALITY INVENTORY; PSYCHOMETRICS; REFERENCE VALUES; SEROTONIN;

EID: 53749099720     PISSN: 00223999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychores.2008.03.016     Document Type: Article

References (24)

1. Abramowitz J.S., and Braddock A.E. Hypochondriasis: conceptualization, treatment, and relationship to obsessive-compulsive disorder. Psychiatr Clin North Am 29 (2006) 503-519
2. Creed F., and Barsky A. A systematic review of the epidemiology of somatisation disorder and hypochondriasis. J Psychosom Res 56 (2004) 391-408
3. Kaplan N.M., and Barsky A.J. Hypochondriasis. N Engl J Med 346 (2002) 783-784
4. Forister J.G., and James B. Hypochondriasis: meeting the management challenge. JAAPA 20 (2007) 42-46
5. Greeven A., van Balkom A.J., van Rood Y.R., van Oppen P., and Spinhoven P. The boundary between hypochondriasis and obsessive-compulsive disorder: a cross-sectional study from the Netherlands. J Clin Psychiatry 67 (2006) 1682-1689
6. Creed F. Should general psychiatry ignore somatization and hypochondriasis?. World Psychiatry 5 (2006) 146-150
7. Castrén E., Võikar V., and Rantamäki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol 7 (2007) 18-21
8. Duman R.S., and Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59 (2006) 1116-1127
9. Martinowich K., Manji H., and Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci 10 (2007) 1089-1093
10. Hall D., Dhilla A., Charalambous A., Gogos J.A., and Karayiorgou M. Sequence variants of the brain-derived neurotrophic factor (BDNF) gene are strongly associated with obsessive-compulsive disorder. Am J Hum Genet 73 (2003) 370-376
11. Malik-Hall M., Dina O.A., and Levine J.D. Primary afferent nociceptor mechanisms mediating NGF-induced mechanical hyperalgesia. Eur J Neurosci 21 (2005) 3387-3394
12. Lautenbacher S., Pauli P., Zaudig M., and Birbaumer N. Attentional control of pain perception: the role of hypochondriasis. J Psychosom Res 44 (1998) 251-259
13. Fallon B.A., Liebowitz M.R., Salman E., Schneier F.R., Jusino C., Hollander E., and Klein D.F. Fluoxetine for hypochondriacal patients without major depression. J Clin Psychopharmacol 13 (1993) 438-441
14. Fallon B.A., Qureshi A.I., Schneier F.R., Sanchez-Lacay A., Vermes D., Feinstein R., Connelly J., and Liebowitz M.R. An open trial of fluvoxamine for hypochondriasis. Psychosomatics 44 (2003) 298-303
15. Greeven A., van Balkom A.J., Visser S., Merkelbach J.W., van Rood Y.R., van Dyck R., et al. Cognitive behavior therapy and paroxetine in the treatment of hypochondriasis: a randomized controlled trial. Am J Psychiatry 164 (2007) 91-99
16. Pilowsky I. Dimensions of hypochondriasis. Br J Psychiatry 113 (1967) 89-93
17. Fink P., Ewald H., Jensen J., Sørensen L., Engberg M., Holm M., and Munk-Jørgensen P. Screening for somatization and hypochondriasis in primary care and neurological in-patients: a seven-item scale for hypochondriasis and somatization. J Psychosom Res 46 (1999) 261-273
18. Schulz E., Fleischhaker C., Clement H.W., and Remschmidt H. Blood biogenic amines during clozapine treatment of early-onset schizophrenia. J Neural Transm 104 (1997) 1077-1089
19. Noga O., Hanf G., Schäper C., O'Connor A., and Kunkel G. The influence of inhalative corticosteroids on circulating Nerve Growth Factor, Brain-Derived Neurotrophic Factor and Neurotrophin-3 in allergic asthmatics. Clin Exp Allergy 31 (2001) 1906-1912
20. Kimata H. Kissing reduces allergic skin wheal responses and plasma neurotrophin levels. Physiol Behav 80 (2003) 395-398
21. Mattson M.P., Maudsley S., and Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 27 (2004) 589-594
22. Je H.S., Yang F., Zhou J., and Lu B. Neurotrophin 3 induces structural and functional modification of synapses through distinct molecular mechanisms. J Cell Biol 175 (2006) 1029-1042
23. Arenas E., and Persson H. Neurotrophin-3 prevents the death of adult central noradrenergic neurons in vivo. Nature 367 (1994) 368-371
24. Politi P., and Emanuele E. Successful treatment of refractory hypochondriasis with duloxetine. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007) 1145-1146